A retrospective analysis was performed on the results of comprehensive genetic profiling collected from 46 patients with a cancer diagnosis utilizing Foundation Medicine’s FoundationOne technology over a 3-year period. Each case was reviewed for the number of genomic alterations identified, the treatment associated with potential for clinical trial benefit, therapies associated with lack of response, and clinical decisions made due to the genomic profiling findings.

A total of 263 genomic alterations were identified in this patient population. Of these patients, 13% were referred to clinical trials, and 26% of their genetic profiling results spurred a change in therapy. Among those diagnosed with lung cancer, 6% were referred to clinical trials, and 34% had a change in therapy.

“We’re thrilled to have achieved our goal, analyzing how information obtained in genomic profiling can impact or change patient care,” said Ms. Rohan. “Our findings, ranging from 6% to 13% of patients referred to clinical trials, exceed the national clinical trial enrollment and highlight a substantial opportunity for patients undergoing cancer treatment.”

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.